CRH Payment for contingent consideration liability (financing) increased by 300.0% to $12.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $11.00M to $12.00M. Over 4 years (FY 2021 to FY 2025), Payment for contingent consideration liability (financing) shows relatively stable performance with a 1.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates higher cash outflows for past acquisitions, potentially signaling successful performance milestones being met by acquired entities.
Represents cash outflows related to the settlement of earn-out or milestone payments for acquired businesses that exceed...
Common in high-growth medical device companies that frequently acquire smaller technology firms.
cf_abbv_payment_contingent_consideration_financing| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.25M | $7.25M | $7.25M | $6.00M | $6.00M | $6.00M | $6.00M | $4.00M | $0.00 | $4.00M | $14.00M | $7.00M | $3.00M | $6.00M | $5.00M | $11.00M | $2.00M | $15.00M | $3.00M | $12.00M |
| QoQ Change | — | +0.0% | +0.0% | -17.2% | +0.0% | +0.0% | +0.0% | -33.3% | -100.0% | — | +250.0% | -50.0% | -57.1% | +100.0% | -16.7% | +120.0% | -81.8% | +650.0% | -80.0% | +300.0% |
| YoY Change | — | — | — | — | -17.2% | -17.2% | -17.2% | -33.3% | -100.0% | -33.3% | +133.3% | +75.0% | — | +50.0% | -64.3% | +57.1% | -33.3% | +150.0% | -40.0% | +9.1% |